-1(1).png)
.png)
.png)
ABSTRACT
Objective: We aimed to evaluate the effect of testosterone treatment (TT) on cardiovascular risk markers in male patients with isolated hypogonadotropic hypogonadism (IHH).
Material and Methods: We included 50 men with IHH who were admitted to the Kahramanmaraş Sütçü İmam University Endocrinology and Metabolism Clinic and 43 healthy men (the control group). The men in the patient group were compared before and after one year of treatment in terms of total testosterone, fasting plasma glucose, alanine aminotransferases (ALT), high-density lipoprotein-cholesterol (HDL-C), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), platelet volume indices [mean platelet volume and platelet distribution width (PDW)], platelet count, and carotid intima-media thickness (CIMT). Moreover, the patient group was compared with the control group.
Results: The mean age of the men in the patient and control groups was 31.6 and 29.6 years, respectively. Patients were divided into pre- (patient group0) and posttreatment (patient group1) groups. The levels of CIMT, TG, and ALT were significantly higher and that of HDL-C was significantly lower in the patient group0 than the control group (p<0.05). Moreover, the level of body mass index, CIMT, ALT, and LDLC was significantly lower and that of HDL-C, platelet count, and PDW was significantly higher (p<0.05) in the patient group1 than the patient group0. A statistically significant negative correlation was observed between testosterone levels and LDL-C, TG, ALT, and CIMT levels (r=-0.207, p=0.047; r=-0.265, p=0.010; r=-0.266, p=0.010; and r=-0.410, p<0.001, respectively), and a positive correlation was observed between HDL-C and testosterone levels (r=0.270, p=0.009).
Conclusion: Our study showed that atherosclerosis risk increases in untreated hypogonadal men. TT has beneficial effects on ALT, CIMT, and lipid profiles. The decrease in ALT after TT may be an indicator of regression in atherosclerosis and a positive response to treatment.